We are pulmonary hypertension (PH) professionals united in our vision for a world without pulmonary vascular disease (PVD). We believe we can achieve this together, and we won’t stop until we do.
PVRI 2026 Awards — Nominations now open
Help us celebrate excellence in PH research and care. PVRI members can now nominate colleagues for our 2026 Awards, to be presented at the Gala Dinner in Dublin. Deadline is 1 December 2025.
Our PVRI Digital Webinar Series alternates between 'Cutting Edge Innovation in Clinical & Experimental PH' and 'Living Legends in PH: History & Personal Perspectives' sessions. Don't miss out!
This November, we’re coming together as one global team to shine a light on PH research and innovation during PH Awareness month through our new fundraising challenge: Breath Beyond Borders. PVRI friends across the world are taking on a personal challenge that pushes their limits. Find out how you can get involved.
Join us 28 January – 1 February as we celebrate 20 years of progress and innovation in PH. This year’s programme highlights advances in PAH, CTEPH, and PH in lung disease, with sessions on emerging therapies, precision medicine, and future directions.
'Microbes/Parasites and Sex Differences in PVDs' is part of the Virtual Symposium Series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
The 'Living Legends in PH: History and Personal Perspectives' talks will feature remarkable people who have made major contributions to the field of pulmonary hypertension, bringing their science and personal stories to the worldwide PH community. Each talk will include a junior and senior facilitator to introduce the speaker and lead the discussion.
This webinar brings together leading experts to explore the urgent need for new therapies in bronchopulmonary dysplasia-associated pulmonary hypertension. You’ll gain a clear overview of current care, key research gaps, and the real-world challenges of designing meaningful trials for preterm infants — all aimed at advancing treatment for this under-recognised condition.
Pulmonary arterial hypertension (PAH) significantly impacts mortality and quality of life. Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. This study compared the clinical course and treatment patterns of PAH patients from urban and rural settings treated at a single comprehensive care center.
Pulmonary hypertension due to interstitial lung disease (PH-ILD) is associated with high morbidity and mortality. Real-world patients initiating inhaled treprostinil are not well-characterized.
Patients with Eisenmenger syndrome (ES) are at increased risk of thrombotic events, especially in pulmonary vessels. However, both the prevalence and risk factors of pulmonary arterial thrombosis (PAT) have been varied greatly. In this study we sought to examine the prevalence of PAT in adult patients with ES and to identify risk factors.
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. They celebrate notable achievements made by special individuals across the world. The PVRI Lifetime Achievement Award 2025, the PVRI Achievement Awards 2025 and the PVRI Special Recognition Award will be presented at PVRI 2026 Dublin.
We’re excited to announce the relaunch of the PVRI Digital Webinar Series, beginning September 2025. This free monthly series, open to all, brings together the global PH community for keynote presentations, rich discussion, and the opportunity to learn cutting-edge new research.
This PH Awareness Month, we’re inviting you to join the global PVRI community for our very first Breath Beyond Borders challenge. Throughout November, PVRI members and friends around the world will be taking on personal challenges — walking, running, cycling, speed skating, or even playing the piano — to shine a light on PH research and innovation, and raise funds for PVRI along the way.
Our Pulmonary Hypertension Global Patient Survey (PHGPS), the largest survey to date to explore the perspectives of patients with PH at a global scale, has released initial findings from its adult cohort of 3,329 patients living with PH.
